Addiction one of the Largest growing Problem’s in the world today. This Press Release Service will bring you the newest services and research available.
[ad_1]
NEW YORK, Sept. 12, 2023 /PRNewswire/ — The elderberry market is expected to grow by USD 267.98 million from 2022 to 2027, according to Technavio. In addition, the growth momentum of the market will progress at a CAGR of 6.72% during the forecast period. The health benefits of elderberry…
[ad_2]
[ad_1]
“Solea is a multiplier at the center of the practice. It enables dentists to streamline current procedures and expand to new procedures while complementing adjacent technologies,” said Robert L. Gershon, CEO of Convergent Dental. “Our new clinical advisors have years of experience with Solea and understand firsthand the multitude of ways this laser can benefit patients and practices. We look forward to the insights they will bring to our growth strategy as we continue to drive the broad-based adoption of Solea.”
The new Convergent Clinical Advisory Board features the following Solea dentists. Dr. Tim Anderson founded Missouri River Dental as a startup private practice in Bismarck, ND. After receiving his Doctor of Dental Surgery from the University of Minnesota School of Dentistry, he completed his general practice residency at Hennepin County Medical Center (Level 1 Trauma Center).
His practice and philosophy are grounded in the belief that technology helps dentists to work smarter, have more fun, and ignite their passion for their business, all while improving the patient experience and achieving better clinical outcomes. He leverages CAD/CAM, CBCT, 3D printing, and CO2 laser technology to deliver comprehensive, quality oral health care that is patient-centered.
In addition to clinical dentistry, Dr. Anderson maintains a leadership role within the dental profession and lectures on various dental technology topics around the country. He is a Key Opinion Leader (KOL) in the areas of dental lasers and 3D Printing. He invests his time and knowledge as a faculty member at 3D Dentists to help other dental professionals nationally discover what digital technology can do for their practices.
Dr. Jeff Rohde currently maintains an innovative restorative and surgical practice in Santa Barbara, CA. He graduated from UCLA with a bachelor’s degree in microbiology and molecular genetics and a master’s degree in biochemistry. He continued his studies at UCLA in the School of Dentistry, graduating with numerous awards. In 2006, Dr. Rohde became one of the founders of Dentalcompare, an online resource that specializes in helping doctors learn about new products and techniques. His practice integrates multiple technologies including the Solea All-Tissue laser, Cone Beam, CAD/CAM, and 3D printing. Dr. Rohde has authored dozens of articles and is an international speaker, covering topics such as digital dentistry, laser dentistry, advanced surgical techniques, and clear aligner therapy.
Dr. Christopher Blair graduated with a B.Sc. in chemistry from York University before completing his Doctor of Dental Surgery Degree at the University of Toronto where he was the recipient of the Dean’s Gold Medal. After graduation, he completed a general practice residency at The Toronto General Hospital. Dr. Blair now maintains a general practice in Oakville, Ontario. He is an avid cyclist and has often combined his passion for cycling with charitable endeavors. Most notably, Dr. Blair is passionate about his efforts to raise funds to support kids living with cancer and who are cancer survivors and to support cancer research. Through his participation in Tour for Kids and The Ride to Conquer Cancer, Dr. Blair has raised thousands of dollars to support Camp Trillium, Camp Quality, and Camp Oochegeas, as well as The Princess Margaret Cancer Centre.
Dr. Jenny Jackson graduated as valedictorian with a degree in microbiology from North Carolina State before attending the Harvard School of Dental Medicine where she was given the Dean’s Community Service Award and was chosen to be a part of the HSDM/Forsyth Institute Research Academy. With a passion for helping children, Dr. Jackson opened her own practice in Asheville, NC in 2007. She currently serves as immediate past president of the North Carolina Academy of Pediatric Dentistry, is an adjunct assistant professor at University of North Carolina Chapel Hill Dental School, and is recognized as a Fellow of the American Academy of Pediatric Dentistry for leadership and service in the field of Pediatric Dentistry.
Dr. Jared Poplin graduated from the University of Kansas with a B.A. in biology. He earned his Doctorate in Dental Medicine from Temple University School of Dentistry and achieved an additional two-year pediatric residency at St. Christopher’s Hospital for Children in Philadelphia while working in a private pediatric dental office. Dr. Poplin has extensive training and experience in nitrous oxide, general anesthesia, and dental trauma. He is also a Diplomate of the American Board of Pediatric Dentistry. Dr. Poplin has volunteered with the Haitian Health Foundation to provide dental care in the rural villages of Haiti. He excels at working with children who are extremely fearful as well as children with special needs.
To learn more about the Solea® All-Tissue Dental Laser, visit www.ConvergentDental.com.
About Convergent Dental
Convergent Dental, Inc. is a privately owned dental equipment and technology company. The Company’s flagship product, Solea®, is the only CO2 laser to be cleared by the FDA for all-tissue indications and delivers virtually anesthesia-free, blood-free, pain-free experiences that dentists can rely on. Solea is a true breakthrough in dental laser technology that offers a completely different experience for both dentists and patients when compared to traditional instruments or any earlier laser treatment. Solea® enables increased new patient flow, better clinical outcomes, significant efficiency gains, and the addition of new procedures. Follow the company on Instagram, Facebook, and LinkedIn.
Media Contact
Caitlin D’Entremont, Convergent Dental, 1 508-500-5656, [email protected], https://www.convergentdental.com/
Barbara Tabor, Tabor PR, 1 651-230-9192, [email protected]
SOURCE Convergent Dental
[ad_2]
[ad_1]
“Microbiologists and regulators are tasked with answering big and difficult questions, and this can only be achieved by continuing to build our competence, sharing experiences and challenges, and keeping the discipline of pharmaceutical microbiology strong and vibrant,” said conference co-chair Kurt Jaecques, GSK.
“For this year’s conference, PDA and the Program Planning Committee are proud to present a robust program that tackles both current and future issues that will impact pharmaceutical microbiology,” said conference co-chair Vineeta Pradhan, U.S. FDA.
Day one will open with a plenary presentation by three-time cancer survivor Rob Weker, whose story will remind attendees of the enormous purpose of their work in pharmaceutical microbiology. The remainder of the day is packed with concurrent sessions covering multiple, forward-looking topics. Day one concludes with a presentation on pathogen spillover into humans by Assistant Professor of Biology David Kennedy, MD, Pennsylvania State University, who will share insights on a model that will be able to predict the likelihood of microbial transmission. Dr. Kennedy will discuss his research model of using nematodes as a unique host organism and how this model promises to predict future crossovers before they develop into global pandemics.
Day two features more expert discussions of all-important topics like environmental monitoring, risk management and data governance, contamination control strategies, and case studies on the implementation of the new European Union Annex 1: Manufacture of Sterile Medicinal Products.
Day three’s headliner is an eye-opening plenary session featuring Elisabeth Bik, PhD, a scientific integrity consultant and founder of the Science Integrity Digest blog. Dr. Bik will share insights on image duplication, manipulation and other problems in biomedical research. She is known for her work on detecting photomanipulations in scientific publications.
The 18th PDA Pharmaceutical Microbiology Conference concludes with the ever popular “Ask the Regulators” session, where U.S. FDA representatives will field questions posed by the audience.
Click here for more information on the 2023 PDA Pharmaceutical Microbiology Conference.
To request a press pass, click here.
Parenteral Drug Association (PDA) is the leading global provider of science, technology, and regulatory information. The PDA creates awareness and understanding of important issues facing the pharmaceutical and biopharmaceutical community and delivers high-quality, relevant education to the industry. Since its founding in 1946 as a nonprofit organization, PDA has been committed to developing scientifically sound, practical technical information and expertise to advance pharmaceutical / biopharmaceutical manufacturing science and regulation, so members can better serve patients. Go to http://www.pda.org/footer/about-pda to learn more.
Media Contact
Walter Morris, www.pda.org, 1 3016565900, [email protected], www.pda.org
SOURCE www.pda.org
[ad_2]
[ad_1]
RejuvenI & Hodari MD Dermatology is proud to welcome Ramneet Basra, PA-C, and Rubeena Basra, BSN to their team of skilled skincare providers. Born and raised in Yuba City, these sisters have returned to their hometown to provide exceptional cosmetic dermatology services to the community.
YUBA CITY, Calif., Sept. 12, 2023 /PRNewswire-PRWeb/ — Yuba City Natives Join RejuvenI & Hodari MD Dermatology to Offer Best-in-Class Skincare Services
Yuba City, CA – RejuvenI & Hodari MD Dermatology is proud to welcome Ramneet Basra, PA-C, and Rubeena Basra, BSN to their team of skilled skincare providers. Born and raised in Yuba City, these sisters have returned to their hometown to provide exceptional cosmetic dermatology services to the community.
After working as a physician assistant in a local hospital’s emergency room for three years, Ramneet Basra found her passion in dermatology. She completed her training at the Massachusetts College of Pharmacy and Health Sciences in Boston, MA before returning to Yuba City to join Dr. Kafele Hodari’s dermatology practice. Ramneet’s experience in emergency medicine has given her the skills to diagnose and manage a range of medical conditions, including skin diseases. She is passionate about helping her patients feel beautiful and powerful in their skin.
Working alongside Dr. Hodari, Ramneet helps patients develop a comprehensive skincare regimen that includes laser skin treatments, BOTOX, and dermal fillers. As a member of the American Academy of PAs, Ramneet is committed to providing the highest level of care to her patients.
Rubeena Basra, BSN is a registered nurse and a certified nurse injector specializing in cosmetic injectables such as neurotoxins and dermal fillers. She has a background in dermatology and is passionate about helping patients achieve healthy, glowing skin. Her gentle touch and attention to detail ensure that patients leave feeling refreshed and rejuvenated.
RejuvenI & Hodari MD Dermatology offers a wide range of cosmetic dermatology services, including BOTOX, dermal fillers, laser procedures, micro-needling, facials, Body Sculpting and more. Patients can trust that they will receive personalized care and attention from Ramneet, Rubeena, and the rest of the skilled team at Hodari MD Dermatology.
Located just minutes from the intersection of Highway 99 and Colusa Avenue, RejuvenI & Hodari MD serves cosmetic and medical dermatology patients from throughout Sutter County. To schedule an appointment, visit rejuvene.com or call 530.561.5929.
For more information about RejuvenI & Hodari MD Dermatology and its services, visit rejuvenI.com.
Contact: Jennifer Thomson
Address: 1178 Live Oak Blvd, Yuba City, CA 95991
Phone: 530.561.5929
Website: rejuvenI.com
Media Contact
Nichole Volk, PhyNet Dermatology, LLC, 1 6156300805, [email protected], phynet.com
SOURCE PhyNet Dermatology, LLC
[ad_2]
[ad_1]
The AEGEAN trial is a double-blind, placebo-controlled phase 3 study that evaluated the use of perioperative durvalumab in combination with neoadjuvant chemotherapy compared to neoadjuvant chemotherapy alone. The trial involved adults with treatment-naïve resectable NSCLC (stage II-IIIB[N2]; AJCC 8th ed) and ECOG PS 0/1. Patients were randomized to receive either neoadjuvant durvalumab 1500 mg or placebo intravenously (IV) alongside platinum-based CT prior to surgery. Following surgery, patients received durvalumab 1500 mg or placebo IV, respectively. The primary endpoints of the trial were pathological complete response and event-free survival.
The study randomized 802 patients with treatment- naïve resectable NSCLC (stage II-IIIB[N2] and ECOG PS 0/1). Efficacy analyses were performed in the modified intent-to-treat population which comprised 740 patients with no documented EGFR mutations/ALK gene rearrangements (366 in the durvalumab arm and 374 in the placebo arm).
Lobectomy, sleeve resection, or bilobectomy were allowed as planned surgery (at enrolment); the protocol was amended with enrollment ongoing to exclude patients with tumors classified as T4 for any reason other than size (>7 cm) or whose planned surgery was pneumonectomy (originally allowed).
In the modified intent-to-treat population, 80.6% and 80.7% underwent surgery, respectively; 77.6% and 76.7% completed surgery, with disease progression the most common reason for canceled (6.8% vs 7.8%) or non-completed (1.4% vs 2.1% ) surgery. Among treated patients who underwent surgery, 17.3% and 22.2% had delayed surgery, most commonly for logistical reasons (e.g., scheduling issues; 9.5% vs. 12.3%). The median time from the last neoadjuvant treatment dose to surgery was the same in each arm (34.0 days). Among patients who underwent surgery, similar proportions in the durvalumab and placebo arms had open (49.2% vs 50.7%) and minimally invasive procedures (49.2% vs 47.0%); lobectomy (including sleeve resection and bilobectomy) was the most common procedure (88.1% vs 85.4%), followed by pneumonectomy (9.2% vs 9.6%). Among patients who completed surgery, a numerically higher proportion had R0 resection in the durvalumab versus placebo arm (94.7% vs 91.3%).
According to Dr. Mitsudomi, it is encouraging to see these comprehensive outcomes described in a robust phase 3 trial which showed that adding perioperative durvalumab to neoadjuvant CT did not adversely impact the feasibility, type, extent, or timing of surgery in patients with R-NSCLC and was associated with a tolerable surgical safety profile. Further, the addition of durvalumab resulted in numerically higher R0 resection rates.
AEGEAN data from outcomes for patients with documented EGFR mutations are also being presented at IASLC 2023 World Conference on Lung Cancer.
The AEGEAN study was conducted by AstraZeneca (LSE/STO/Nasdaq: AZN).
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2023.iaslc.org
Media Contact
Chris Martin, The David James Group, 6306702745, [email protected], https://wclc2023.iaslc.org
SOURCE International Association for the Study of Lung Cancer
[ad_2]
[ad_1]
“For patients in rural areas, accessing dermatological care can be challenging due to extended wait times or the need to travel long distances to reach the nearest practitioners,” said Paul Singh, Chief Executive Officer of U.S. Dermatology Partners. “We are pleased to offer more accessible care options to patients in St. Joseph through the expansion of our Outreach Program. We look forward to serving the residents of Andrew and Buchanan Counties with the quality dermatologic care they deserve.”
St. Joseph is located in Andrew and Buchanan County and is the county seat of Buchanan County. Located at the crossroads of Interstate 29 and Highway 36, St. Joseph is only 30 minutes from North Kansas City. The city is home to 13 distinctive area museums, 12 annual festivals, architecture listed on the National Register of Historic Places, and the Kansas City Chiefs Summer Training Camp. Residents of St. Joseph also enjoy outdoor recreation throughout 48 parks, 26 miles of beautiful walking paths, outdoor concerts, and an active arts and culture scene.
Today’s announcement builds on U.S. Dermatology Partners’ recent openings of offices in Olathe, Kansas, Canton, Texas, and Frederick, Maryland. The St. Joseph office is conveniently located at 3107 Frederick Ave., #B, St. Joseph, Missouri, 64506. For more information or to schedule an appointment call (816) 205-4123 or click here to request an appointment online.
About U.S. Dermatology Partners
U.S. Dermatology Partners is one of the premier dermatology practices in the country, caring for nearly two million patients each year. With over 100 locations across eight states that span large metroplexes and rural, underserved communities, they provide the benefits of private, personalized levels of care paired with a network of coordinated, specialized dermatology physicians. U.S. Dermatology Partners is fervently focused on providing the highest level of compassionate and comprehensive patient-first care, making it seamless for all people to connect with dermatologists and national leaders in areas such as clinical research, psoriasis, and Mohs surgery and gain access to state-of-the-art dermatological treatments, surgical and cosmetic dermatology. To learn more, visit usdermatologypartners.com.
Media Contact
Jeanne Cunningham, U.S. Dermatology Partners, 2144200655, [email protected], www.usdermatologypartners.com
SOURCE U.S. Dermatology Partners
[ad_2]
[ad_1]
STOCKHOLM, Sept. 12, 2023 /PRNewswire/ — Beactica Therapeutics AB, the Swedish precision oncology company, today announced two appointments to its preclinical development team. Dr Anneli Hällgren will lead the preclinical development and Dr Carl Magnus Andersson will lead the CMC…
[ad_2]
[ad_1]
Dr. Thomas McNemar attended the Medical College of Ohio, where he decided to pursue a surgical career. After completing a general surgery residency at the prestigious Cleveland Clinic, he continued his surgical education at Akron City Hospital as a plastic surgery fellow. Realizing he possessed a natural gift for detail and perfection, he elected to round out his formal education at the Bunke Clinic in San Francisco, California, as an attending fellow specializing in hand and microvascular surgery. He is a diplomate of the American Board of Plastic Surgery and a Fellow of the American College of Surgeons.
To get to know Dr. McNemar, request a consultation using our online form or call (209) 290-1588 for our Tracy office to make your appointment.
Learn more about Dr. Thomas McNemar by visiting:
https://hauteliving.com/hautebeauty/member/dr-thomas-mcnemar/
ABOUT HAUTE BEAUTY NETWORK:
Haute Beauty is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.
For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/
Media Contact
Brooke Klaiman, Haute Beauty by Haute Living, 5612122126, [email protected], https://hauteliving.com/hautebeauty/
SOURCE Haute Beauty by Haute Living
[ad_2]
[ad_1]
Mesothelioma, a rare and aggressive cancer primarily linked to asbestos exposure, has prompted exploration into various treatment options, including surgical procedures like pleurectomy decortication. However, despite its common use, the effectiveness of this intervention has never been evaluated in a randomized trial.
The trial, which enrolled 335 participants, randomly assigned 169 patients with resectable mesothelioma to extended pleurectomy decortication and 166 patients to chemotherapy (platinum and pemetrexed) or chemotherapy alone.
The researchers followed patients for a median 22.4 months.
Patients randomized to surgery and chemotherapy exhibited a median survival of 19.3 months, while those randomized to chemotherapy alone demonstrated a median survival of 24.8 months. However, the hazards for death were non-proportional, prompting the presentation of primary outcomes in two timeframes: randomization to 42 months and beyond 42 months. The analysis indicated a 28% increase in the risk of death in the surgery group within the first 42 months, while no significant difference in survival emerged after 42 months, Lim reported.
Moreover, the research unveiled significant disparities in progression-free survival and adverse events between the two groups. The surgery group experienced a 3.6-fold higher incidence of serious adverse events (CTCAE grade 3 and above), and Dr. Lim reported that patients who underwent surgery reported poorer quality of life and well-being on various EORTC health-related quality of life scales, particularly in global health, physical functioning, social functioning, and role functioning. The surgery group also exhibited worse positive symptom scores, including pain, dyspnea, insomnia, loss of appetite, and financial difficulties.
Prof. Lim concluded that extended pleurectomy decortication should not be offered to patients with pleural mesothelioma and classifying this disease as “unresectable” from the outset would increase access to more effective systemic treatments to improve survival for patients with early-stage disease.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2023.iaslc.org.
Media Contact
Chris Martin, IASLC, 6306702745, [email protected], https://wclc2023.iaslc.org.
SOURCE IASLC
[ad_2]
[ad_1]
After spending over 20 years in the corporate world, Scott decided he needed a revamp and reboot. He discovered Caring Transitions through his sister, who lives in Arizona. Couple that with caring for an ageing parent himself over the last few months, Scott confessed that the services and support that Caring Transitions offered seemed like a natural fit and met his goal of helping others in any new venture he undertook.
“I understand what families go through and the stress it can put on them when you’re trying to juggle your own life, and also have to deal with an emotional and uncertain situation,” Scott said. “Being able to help a family through a challenging time is really valuable, especially because I see myself eventually needing that with my own parent when there needs to be a different living arrangement.”
Caring Transitions of East Stroudsburg will serve East Stroudsburg, Bushkill, Cresco, Dingman’s Ferry, Hawley, Milford, The Poconos, Stroudsburg, Tobyhanna and surrounding areas. Scott is looking forward to helping minimize stress for families during what can be a difficult time in a loved one’s life.
“Going through a transition like moving for seniors can be challenging and fraught with emotion,” Scott said. “Having someone to lighten the load and take charge of details can be extremely beneficial.”
“Scott is certainly somebody that gets it,” said Ray Fabik, President of Caring Transitions. “He empathizes with clients because he himself has an aging parent. It’s clear he cares about his community and his team will be a valuable asset to anyone in the Stroudsburg area who needs help downsizing or re-focusing their living situation.”
To learn more about Caring Transitions, visit http://www.CaringTransitions.com.
For more about franchising opportunities with Caring Transitions, visit https://www.caringtransitionsfranchise.com/.
About Caring Transitions
Caring Transitions, founded in 2006, is the most trusted and experienced national franchise specializing in senior relocation and transition services. With more than 280 locations throughout the United States, all owned and operated by Certified Relocation and Transition Specialists, Caring Transitions provides clients with supportive moves, auctions, rightsizing, and transitions. This includes expert advice plus a well-executed transition plan beginning with the initial sorting of personal belongings through packing, unpacking, resettling, and selling of items to the final clearing and cleaning of the property. For more information, visit http://www.caringtransitions.com or visit us on Facebook.
Media Contact
Mike Toper, 919 Marketing.com, (919) 813-6511, [email protected], 919marketing.com
SOURCE Caring Transitions
[ad_2]
